Literature DB >> 29926172

Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype.

Shunsuke Koga1, Naomi Kouri2, Ronald L Walton1, Mark T W Ebbert1, Keith A Josephs3, Irene Litvan4, Neill Graff-Radford5, J Eric Ahlskog3, Ryan J Uitti5, Jay A van Gerpen5, Bradley F Boeve3, Adam Parks6, Owen A Ross1, Dennis W Dickson7.   

Abstract

Corticobasal degeneration (CBD) is a clinically heterogeneous tauopathy, which has overlapping clinicopathologic and genetic characteristics with progressive supranuclear palsy (PSP). This study aimed to elucidate whether transactive response DNA-binding protein of 43 kDa (TDP-43) pathology contributes to clinicopathologic heterogeneity of CBD. Paraffin-embedded sections of the midbrain, pons, subthalamic nucleus, and basal forebrain from 187 autopsy-confirmed CBD cases were screened with immunohistochemistry for phospho-TDP-43. In cases with TDP-43 pathology, additional brain regions (i.e., precentral, cingulate, and superior frontal gyri, hippocampus, medulla, and cerebellum) were immunostained. Hierarchical clustering analysis was performed based on the topographical distribution and severity of TDP-43 pathology, and clinicopathologic and genetic features were compared between the clusters. TDP-43 pathology was observed in 45% of CBD cases, most frequently in midbrain tegmentum (80% of TDP-43-positive cases), followed by subthalamic nucleus (69%). TDP-43-positive CBD was divided into TDP-limited (52%) and TDP-severe (48%) by hierarchical clustering analysis. TDP-severe patients were more likely to have been diagnosed clinically as PSP compared to TDP-limited and TDP-negative patients (80 vs 32 vs 30%, P < 0.001). The presence of downward gaze palsy was the strongest factor for the antemortem diagnosis of PSP, and severe TDP-43 pathology in the midbrain tectum was strongly associated with downward gaze palsy. In addition, tau burden in the olivopontocerebellar system was significantly greater in TDP-positive than TDP-negative CBD. Genetic analyses revealed that MAPT H1/H1 genotype frequency was significantly lower in TDP-severe than in TDP-negative and TDP-limited CBD (65 vs 89 vs 91%, P < 0.001). The homozygous minor allele frequencies in GRN rs5848 and TMEM106B rs3173615 were not significantly different between the three groups. In conclusion, the present study indicates that CBD with severe TDP-43 pathology is a distinct clinicopathologic subtype of CBD, characterized by PSP-like clinical presentations, severe tau pathology in the olivopontocerebellar system, and low frequency of MAPT H1 haplotype.

Entities:  

Keywords:  Argyrophilic grain disease; Corticobasal degeneration; Corticobasal syndrome; MAPT; Progressive supranuclear palsy; TDP-43

Mesh:

Substances:

Year:  2018        PMID: 29926172      PMCID: PMC6309287          DOI: 10.1007/s00401-018-1878-z

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  66 in total

1.  Does corticobasal degeneration exist? A clinicopathological re-evaluation.

Authors:  Helen Ling; Sean S O'Sullivan; Janice L Holton; Tamas Revesz; Luke A Massey; David R Williams; Dominic C Paviour; Andrew J Lees
Journal:  Brain       Date:  2010-07       Impact factor: 13.501

2.  Cognitive impairment in progressive supranuclear palsy is associated with tau burden.

Authors:  Shunsuke Koga; Adam Parks; Koji Kasanuki; Monica Sanchez-Contreras; Matthew C Baker; Keith A Josephs; J Eric Ahlskog; Ryan J Uitti; Neill Graff-Radford; Jay A van Gerpen; Zbigniew K Wszolek; Rosa Rademakers; Dennis W Dickson
Journal:  Mov Disord       Date:  2017-10-30       Impact factor: 10.338

3.  Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease.

Authors:  B T Hyman; J Q Trojanowski
Journal:  J Neuropathol Exp Neurol       Date:  1997-10       Impact factor: 3.685

Review 4.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop.

Authors:  I Litvan; Y Agid; D Calne; G Campbell; B Dubois; R C Duvoisin; C G Goetz; L I Golbe; J Grafman; J H Growdon; M Hallett; J Jankovic; N P Quinn; E Tolosa; D S Zee
Journal:  Neurology       Date:  1996-07       Impact factor: 9.910

5.  Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated.

Authors:  John L Robinson; Edward B Lee; Sharon X Xie; Lior Rennert; EunRan Suh; Colin Bredenberg; Carrie Caswell; Vivianna M Van Deerlin; Ning Yan; Ahmed Yousef; Howard I Hurtig; Andrew Siderowf; Murray Grossman; Corey T McMillan; Bruce Miller; John E Duda; David J Irwin; David Wolk; Lauren Elman; Leo McCluskey; Alice Chen-Plotkin; Daniel Weintraub; Steven E Arnold; Johannes Brettschneider; Virginia M-Y Lee; John Q Trojanowski
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

6.  Neuroanatomical correlates of the progressive supranuclear palsy corticobasal syndrome hybrid.

Authors:  K A Josephs; S D Z Eggers; C R Jack; J L Whitwell
Journal:  Eur J Neurol       Date:  2012-04-23       Impact factor: 6.089

7.  Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies.

Authors:  Kunihiro Uryu; Hanae Nakashima-Yasuda; Mark S Forman; Linda K Kwong; Christopher M Clark; Murray Grossman; Bruce L Miller; Hans A Kretzschmar; Virginia M-Y Lee; John Q Trojanowski; Manuela Neumann
Journal:  J Neuropathol Exp Neurol       Date:  2008-06       Impact factor: 3.685

8.  Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

Authors:  Günter U Höglinger; Gesine Respondek; Maria Stamelou; Carolin Kurz; Keith A Josephs; Anthony E Lang; Brit Mollenhauer; Ulrich Müller; Christer Nilsson; Jennifer L Whitwell; Thomas Arzberger; Elisabet Englund; Ellen Gelpi; Armin Giese; David J Irwin; Wassilios G Meissner; Alexander Pantelyat; Alex Rajput; John C van Swieten; Claire Troakes; Angelo Antonini; Kailash P Bhatia; Yvette Bordelon; Yaroslau Compta; Jean-Christophe Corvol; Carlo Colosimo; Dennis W Dickson; Richard Dodel; Leslie Ferguson; Murray Grossman; Jan Kassubek; Florian Krismer; Johannes Levin; Stefan Lorenzl; Huw R Morris; Peter Nestor; Wolfgang H Oertel; Werner Poewe; Gil Rabinovici; James B Rowe; Gerard D Schellenberg; Klaus Seppi; Thilo van Eimeren; Gregor K Wenning; Adam L Boxer; Lawrence I Golbe; Irene Litvan
Journal:  Mov Disord       Date:  2017-05-03       Impact factor: 10.338

9.  Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration.

Authors:  Jennifer Gass; Ashley Cannon; Ian R Mackenzie; Bradley Boeve; Matt Baker; Jennifer Adamson; Richard Crook; Stacey Melquist; Karen Kuntz; Ron Petersen; Keith Josephs; Stuart M Pickering-Brown; Neill Graff-Radford; Ryan Uitti; Dennis Dickson; Zbigniew Wszolek; John Gonzalez; Thomas G Beach; Eileen Bigio; Nancy Johnson; Sandra Weintraub; Marsel Mesulam; Charles L White; Bryan Woodruff; Richard Caselli; Ging-Yuek Hsiung; Howard Feldman; Dave Knopman; Mike Hutton; Rosa Rademakers
Journal:  Hum Mol Genet       Date:  2006-09-01       Impact factor: 6.150

10.  The disturbance of gaze in progressive supranuclear palsy: implications for pathogenesis.

Authors:  Athena L Chen; David E Riley; Susan A King; Anand C Joshi; Alessandro Serra; Ke Liao; Mark L Cohen; Jorge Otero-Millan; Susana Martinez-Conde; Michael Strupp; R John Leigh
Journal:  Front Neurol       Date:  2010-12-03       Impact factor: 4.003

View more
  22 in total

1.  Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy.

Authors:  Farwa Ali; Peter R Martin; Hugo Botha; J Eric Ahlskog; James H Bower; Joseph Y Masumoto; Demetrius Maraganore; Anhar Hassan; Scott Eggers; Bradley F Boeve; David S Knopman; Daniel Drubach; Ronald C Petersen; Erika Driver Dunkley; Jay van Gerpen; Ryan Uitti; Jennifer L Whitwell; Dennis W Dickson; Keith A Josephs
Journal:  Mov Disord       Date:  2019-02-06       Impact factor: 10.338

Review 2.  Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes.

Authors:  Ralph Buchert; Carsten Buhmann; Ivayla Apostolova; Philipp T Meyer; Jürgen Gallinat
Journal:  Dtsch Arztebl Int       Date:  2019-11-01       Impact factor: 5.594

3.  Microglial depletion prevents extracellular matrix changes and striatal volume reduction in a model of Huntington's disease.

Authors:  Joshua D Crapser; Joseph Ochaba; Neelakshi Soni; Jack C Reidling; Leslie M Thompson; Kim N Green
Journal:  Brain       Date:  2020-01-01       Impact factor: 13.501

4.  Cerebrovascular pathology presenting as corticobasal syndrome: An autopsy case series of "vascular CBS".

Authors:  Shunsuke Koga; Shanu F Roemer; Koji Kasanuki; Dennis W Dickson
Journal:  Parkinsonism Relat Disord       Date:  2019-09-02       Impact factor: 4.891

Review 5.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

Review 6.  The Role of TDP-43 in Neurodegenerative Disease.

Authors:  Yan-Zhe Liao; Jing Ma; Jie-Zhi Dou
Journal:  Mol Neurobiol       Date:  2022-05-02       Impact factor: 5.590

7.  Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD.

Authors:  John L Robinson; Ning Yan; Carrie Caswell; Sharon X Xie; EunRan Suh; Vivianna M Van Deerlin; Garrett Gibbons; David J Irwin; Murray Grossman; Edward B Lee; Virginia M-Y Lee; Bruce Miller; John Q Trojanowski
Journal:  J Neuropathol Exp Neurol       Date:  2020-03-01       Impact factor: 3.685

8.  Machine learning-based decision tree classifier for the diagnosis of progressive supranuclear palsy and corticobasal degeneration.

Authors:  Shunsuke Koga; Xiaolai Zhou; Dennis W Dickson
Journal:  Neuropathol Appl Neurobiol       Date:  2021-04-07       Impact factor: 6.250

Review 9.  Frontotemporal lobar degeneration with TAR DNA-binding protein 43 (TDP-43): its journey of more than 100 years.

Authors:  Arenn F Carlos; Keith A Josephs
Journal:  J Neurol       Date:  2022-03-23       Impact factor: 6.682

10.  Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia.

Authors:  Mercedes Prudencio; Jack Humphrey; Sarah Pickles; Anna-Leigh Brown; Sarah E Hill; Jennifer M Kachergus; J Shi; Michael G Heckman; Matthew R Spiegel; Casey Cook; Yuping Song; Mei Yue; Lillian M Daughrity; Yari Carlomagno; Karen Jansen-West; Cristhoper Fernandez de Castro; Michael DeTure; Shunsuke Koga; Ying-Chih Wang; Prasanth Sivakumar; Cristian Bodo; Ana Candalija; Kevin Talbot; Bhuvaneish T Selvaraj; Karen Burr; Siddharthan Chandran; Jia Newcombe; Tammaryn Lashley; Isabel Hubbard; Demetra Catalano; Duyang Kim; Nadia Propp; Samantha Fennessey; Delphine Fagegaltier; Hemali Phatnani; Maria Secrier; Elizabeth Mc Fisher; Björn Oskarsson; Marka van Blitterswijk; Rosa Rademakers; Neil R Graff-Radford; Bradley F Boeve; David S Knopman; Ronald C Petersen; Keith A Josephs; E Aubrey Thompson; Towfique Raj; Michael Ward; Dennis W Dickson; Tania F Gendron; Pietro Fratta; Leonard Petrucelli
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 19.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.